Related Experiment Videos
Fenfluramine increases insulin action in patients with NIDDM
R G Pestell1, P A Crock, G M Ward
1University of Melbourne, Department of Medicine, St. Vincent's Hospital, Victoria, Australia.
Diabetes Care
|April 1, 1989
Summary
Fenfluramine improved glucose control in non-insulin-dependent diabetes mellitus (NIDDM) patients by enhancing insulin action and clearance. However, it did not affect insulin secretion or sensitivity in healthy subjects.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Non-insulin-dependent diabetes mellitus (NIDDM) is characterized by impaired insulin action and secretion.
- Understanding the effects of pharmacological agents on glucose metabolism is crucial for NIDDM management.
Purpose of the Study:
- To investigate the impact of fenfluramine on insulin action and insulin secretion.
- To evaluate fenfluramine's efficacy in healthy individuals and NIDDM patients.
Main Methods:
- Double-blind crossover studies were conducted in healthy subjects and NIDDM patients.
- Insulin sensitivity was assessed using frequently sampled intravenous glucose tolerance tests and euglycemic-hyperinsulinemic clamp studies.
- Fasting blood glucose, serum insulin, and C-peptide levels were measured.
Main Results:
- Fenfluramine did not alter insulin secretion or whole-body insulin sensitivity in healthy subjects.
- In NIDDM patients, fenfluramine significantly reduced fasting blood glucose levels.
- Fenfluramine enhanced insulin action and increased insulin metabolic clearance rate in NIDDM patients.
Conclusions:
- Fenfluramine demonstrates potential in improving glycemic control in NIDDM patients.
- The drug enhances insulin action and clearance, but its effects on healthy individuals are limited.
- Further research is warranted to explore fenfluramine's therapeutic role in diabetes management.